Which hedge funds own NKTR? NEKTAR THERAPEUTICS, Q2 2026 13F holders
Healthcare · Open on the interactive board
6 of the hedge funds tracked by WhaleCreep disclosed a position in NKTR (NEKTAR THERAPEUTICS) in their Q2 2026 13F filings, worth $93.0m in total. The largest holder by portfolio weight is Bronte Capital at 1.6% of its book. 3 exited: Farallon Capital Management, Point72 Asset Management LP, Renaissance Technologies LLC.
6tracked managers holding
0opened this quarter
3exited this quarter
Which hedge funds hold NKTR? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Bronte Capital | Q2 2026 | 1.6% | $13.9m | 198,434 | 0% | held |
| Woodline Partners | Q2 2026 | 0.1% | $32.9m | 470,875 | 13% | added |
| Millennium Management | Q2 2026 | 0.0% | $33.4m | 478,120 | 18% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $1.5m | 21,918 | -55% | reduced |
| Citadel Advisors | Q2 2026 | 0.0% | $11.2m | 159,747 | -69% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $230.4k | 3,300 | -98% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Farallon Capital Management | 0.0% | $287.8k |
| Point72 Asset Management LP | 0.0% | $961.5k |
| Renaissance Technologies LLC | 0.1% | $3.0m |
How has hedge fund ownership of NKTR changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 6 | $93.0m |
| Q1 2026 | 10 | $129.1m |
| Q4 2025 | 3 | $30.0m |
| Q3 2025 | 5 | $81.5m |
| Q2 2025 | 2 | $12.7m |
| Q1 2025 | 3 | $5.7m |
| Q4 2024 | 3 | $8.3m |
| Q3 2024 | 3 | $6.7m |
| Q2 2024 | 3 | $5.0m |
| Q1 2024 | 3 | $4.4m |
| Q4 2023 | 3 | $3.0m |
| Q3 2023 | 5 | $14.2m |
| Q2 2023 | 4 | $2.4m |
| Q1 2023 | 4 | $2.2m |
| Q4 2022 | 5 | $1.5m |
| Q3 2022 | 4 | $1.0m |
Counts every tracked manager that disclosed NKTR in that quarter's filing, including managers that have since stopped filing.